Oncology · Colorectal CancerTrial Updateclinicalmid-term

Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:31:01 AM

Assessment confidence: 64% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of onvansertib in combination with standard therapies for metastatic colorectal cancer could significantly impact treatment options for patients with specific mutations. Success in this trial may enhance Cardiff Oncology's portfolio and strengthen its collaboration with Pfizer, positioning them competitively in the oncology market. Regulatory context from FDA (FDA AP — INQOVI (SUPPL)) supports the near-term read. Assessment grounded in 17 ranked evidence items (8 high-relevance).

Strategic Assessment

Success in this trial could enhance Cardiff Oncology's portfolio and strengthen its partnership with Pfizer, potentially leading to a new treatment paradigm in CRC. The strongest clinical anchor is Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Ca (ClinicalTrials.gov), sub-indication match (colorectal cancer); mechanism alignment (kras). In colorectal cancer, 5 regulatory and 0 competitive items passed relevance filtering for Pfizer.

Competitive Pressure

The most relevant competitive pressure comes from This trial may position onvansertib as a competitive option in the treatment landscape for metastatic colorectal cancer, particularly among patients with specific mutations..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — INQOVI (SUPPL) (FDA). Sponsor/company relevance (Pfizer); Regulatory pathway relevance (nda). The trial's outcomes will be critical for potential regulatory approvals and labeling, especially given the focus on specific genetic mutations that may influence treatment pathways.

Key Risks

Elevated medium regulatory exposure for Pfizer could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Pfizer through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If successful, onvansertib could capture a significant share of the metastatic colorectal cancer market, particularly among patients with KRAS/NRAS mutations, leading to increased revenues for both Cardiff Oncology and Pfizer.
Upside for Pfizer may improve if Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Ca (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Pfizer may improve if Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells. (PubMed) delivers favorable follow-through.
Upside for Pfizer may improve if Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (ClinicalTrials.gov) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for efficacy and safety, particularly the selection of the optimal dosing regimen.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Pfizer); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Sponsor/company relevance (Pfizer); Regulatory pathway relevance (nda)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Ca
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Mechanism alignment (KRAS)
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Pfizer); Patient population match (metastatic)
FDA document
View source
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Pfizer); Patient population match (metastatic)
FDA document
View source
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
ClinicalTrials.govlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway
Humanexa Signalslow relevance
Entity match (pfizer)

Discovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Mechanism alignment (KRAS)
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Genetic variants of the transporter SLC22A4 affect the abundance and survival of Fusobacterium nucleatum in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
Altered crosstalk of bacterial lipopolysaccharide with immune cells in colorectal cancer compared to paired adjacent intestinal tissue.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Pfizer)
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Pfizer
metastatic colorectal cancer
Cardiff Oncology

Commercial impact

high

If successful, onvansertib could capture a significant share of the metastatic colorectal cancer market, particularly among patients with KRAS/NRAS mutations, leading to increased revenues for both Cardiff Oncology and Pfizer.

Regulatory impact

medium

The trial's outcomes will be critical for potential regulatory approvals and labeling, especially given the focus on specific genetic mutations that may influence treatment pathways.

What to watch

Monitor trial results for efficacy and safety, particularly the selection of the optimal dosing regimen.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.